Starting PrEP does not lead to more STIs, youth survey in Chicago finds
Who stops taking PrEP, and why?
Islatravir plus doravirine may offer new dual therapy option
Trial vaccine could protect against HIV for more than five years
Four days on, three days off HIV treatment as effective as continuous therapy, French study finds
ADVANCE trial shows dolutegravir is highly effective in South Africa
Three forms of PrEP stigma in Kenya
PrEP implant could last well over a year
WHO endorses event-driven PrEP for gay men
